Medical Developments International

Road Show

Medical Developments International

Disclaimer

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

There can be no assurance that any existing or future regulatory filings will satisfy any health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Any statements regarding earnings is not a profit forecast and should not be interpreted to mean that Medical Developments International's earnings for this year or any subsequent period will necessarily match or exceed the historical published earnings of Medical Developments International. Medical Developments International Limited, its directors, officers and employees do not accept any liability whatsoever for any damage or loss caused by anything contained in this document.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com

Vision

Medical Developments International (MDI) is a leading Emergency Medicine Company.

Our aim is to:

1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader in these markets globally.
2. Provide unique and innovative products to assist our customers in the management of delivery of respiratory medications, resuscitation and oxygen therapies and to be the market leader in Medical Devices for Asthma and COPD markets globally.

The Business

MDI is delivering two world class “company making” business opportunities.

The risk profile of these opportunities is relatively low and well understood.

Penthrox: Penthrox has the potential to be the market leader in acute pain markets around the world. Penthrox is not an opiate and delivers time and cost savings. It is the pain solution for acute pain, trauma and minor surgical procedures.

Our Respiratory Medical Devices are amongst the world’s best and will generate significant growth.

Key achievements of H1FY17

Key achievements of H1FY17

Penthrox®

- ☑ First sales of Penthrox® in France and Belgium
- ☑ National reimbursement of Penthrox® in France
- ☑ Submitted Regulatory Applications to have Penthrox® approved in 22 countries
- ☑ Regulatory approval in the UAE
- ☑ Regulatory approval in Taiwan
- ☑ Distribution deal signed with Purdue Pharma in Canada
- ☑ Distribution deal signed with BL&H Co Ltd Corporation for Korea
- ☑ Received upfront payments from Korea and Canada
- ☑ Submitted two new Global Patent Applications for Penthrox® Inhalers
- ☑ Enrolled first patient in Penthrox® Post Authorisation Safety Study in Europe
- ☑ Commenced pre-clinical and clinical work for FDA approval
- ☑ Commenced planning pre-clinical and clinical work for Penthrox® indication extensions

Key achievements of H1FY17

Respiratory Medical Devices

- ☑ Global sales growth of 142%
- ☑ Signed new distribution deal in USA with McKesson
- ☑ Sales growth of 148% for USA
- ☑ First sales into 1,600 pharmacies in the USA. More to follow
- ☑ Sales growth of 192% in Australia
- ☑ Record sales for Breath-A-Tech®
- ☑ Sales growth of 159% in UK and Europe
- ☑ Sales growth of 41% in New Zealand
- ☑ Patent Application for new respiratory devices
- ☑ Launch of six new respiratory products

Key achievements of H1FY17

Corporate

- ☑ $5.5 million cash in bank
- ☑ No debt
- ☑ Construction of new manufacturing facility on time and on budget. Due for completion in March 2017
- ☑ Continued investment in new product development
- ☑ PDCO approval of Paediatric Study protocol, first patient expected July 2017
- ☑ MVP has 9 Patent and Patent applications
- ☑ MVP has Trademarks in over 30 countries

Introducing Penthrox

Penthrox®

A world class opportunity

Penthrox®

- Market Leader for trauma pain
- Opiate sparing, fast acting inhalational analgesic
- 85% of patients reach clinical analgesia within 10 breaths[1]
- Is a solution to a significant unmet clinical need
- Demonstrated safety and efficacy profile for 30+ years
- World class regulatory dossier completed and being used to generate regulatory approvals around the world (*work commenced in USA*)
- Manufactured in Australia

1 Coffey (2014)- STOP!: A Randomised, Double-blind, Placebo-controlled Study Of The Efficacy & Safety Of Methoxyflurane For The Treatment Of Acute Pain

Penthrox

A world class opportunity

Penthrox®

- Sold in 17 countries around the world including Australia, UK, France, Ireland , South Africa, Singapore, Belgium, New Zealand, UAE, Qatar and elsewhere.
- Major distribution deals signed in Europe and elsewhere in 2015.
- $18.5 million in upfronts and milestones received.
- Sales commenced in UK, Ireland, Singapore, France and Belgium.
- Six patent applications lodged covering new Penthrox delivery devices.
- Patent application lodged covering new Penthrox manufacturing technology.

Penthrox®

History and planned launches



Penthrox®

Clinical application

Painful procedures

- Burn injuries
- Breaks, fractures and dislocations
- Abdomen pain
- Chest pain
- Other acute pain



Painful procedures

- Cutaneous excisions
- Liquid nitrogen removals of skin-cancers, warts, etc.
- Invasive angiographies
- Dental procedures
- Colonoscopy
- Imaging
- Other non-general anaesthetic painful procedures
- Cosmetic procedures

Either as an adjunct to or replacement of current forms of pain relief

Penthrox

Benefits to medical professionals

Rapid onset of action	Minimal waiting time before a painful procedure can be performed (3 minutes) and rapid pain relief when a patient is treated for acute pain, trauma, and minor surgical procedures.
Inhaled self-administration	Medical professionals can perform a procedure/attend to an injury whilst the patient is self-administering with minimal supervision needed.
Improve patient compliance	Fastest time to analgesia and effective at calming patients before procedures; makes patients more compliant and cooperative during treatments/procedures. No known drug to drug interaction. Patients can drive themselves home and go back to work after 30 minutes.
Portable, easy to use	Easy to store in a range of clinical settings (hospital ER, ambulance, GP/specialist consulting rooms, hospital departments, military unit, etc).
Opiate sparing	Addiction and the use of narcotics is increasingly problematic. Penthrox is non narcotic and non addictive, making it the better solution for medical professionals.

Penthrox

Benefits over Opiates

The benefits of using Penthrox® over Morphine include:

- Penthrox does not effect vital signs; no clinical depression of respiration or circulation.
- Penthrox can be used on children, Morphine often cannot.
- Penthrox is not a narcotic, nor is it an opioid or drug of addiction.
- Penthrox has less severe side effects.
- Penthrox is non invasive – no needles.
- Penthrox has a quicker onset to pain relief, improves time to analgesia.
- Penthrox can be used by a wider community of health professionals including first aiders and volunteers.
- Morphine has considerable, expensive and complex administration and monitoring protocols during its use and for a significant time during recovery.
- After using Penthrox there is no long observation period needed before patients can go home (possibly drive themselves home after 30 minutes).
- Penthrox does not require specific storage and use protocols (is not a restricted medicine).
- Penthrox can be disposed of easily and safely.

Penthrox

Benefits over Nitrous Oxide

The benefits of using Penthrox® over Nitrous Oxide include:

- Penthrox does not effect vital signs; no clinical depression of respiration or circulation.
- Penthrox is self-administered and easy to use.
- Penthrox is compact and can be used in any location or situation.
- Penthrox does not carry any risk of overdose.
- Single use device ensures no cleaning or cross contamination.
- Medical professionals can perform a procedure / attend to an injury almost immediately whilst the patient is self-administering with minimal supervision.
- Penthrox offset ranges from 3-5 minutes up to 20 minutes.
- Penthrox is easy and stable to store.
- After using Penthrox there is no long observation period needed before patients can go home (possibly drive themselves).

Penthrox

Non-narcotic and clinically proven efficacy

VAS scores compared, IV morphine vs IN fentanyl vs Penthrox

Summary of mean VAS Pain Scores						
Time	**0**	**5 minutes**	**10 minutes**	**15 minutes**	**20 minutes**	**30 minutes**
Morphine	67	42	41	-	35	33
Fentanyl	68	55	46	-	37	37
Penthrox®	65	43	37	31	30	-
Summary of mean reduction in VAS Pain Scores						
Time	**0**	**5 minutes**	**10 minutes**	**15 minutes**	**20 minutes**	**30 minutes**
Morphine	0	25	26	-	32	34
Fentanyl	0	13	22	-	31	31
Penthrox®	0	22	28	34	35	-

The criteria for the cross study comparison were a similar study design and endpoint as the Penthrox® study, MEOF-001. Borland et al (2007) has a similar study design and endpoints as those of MEOF-001 (Table 2). Borland et al (2007) compared two active drugs, IV morphine against IN fentanyl. The VAS scores observed for the three drugs at Baseline, 5, 10, 20 and 30 minutes are compared in Table 1 . The results demonstrate that Penthrox® is as effective as the alternate opioid analgesic agents that are currently used in A&E but has a significantly better safety profile. Treatment with Penthrox® does not result in respiratory depression as demonstrated in clinical trials of the development programme – MEOF-001, 06/61, MEOF-003. The retrospective observational study Vital Signs Report (see Vital Signs Report) showed no deleterious effects on pulse rate, systolic BP, or respiratory rate. Methoxyflurane has negligible effects on the cardiovascular system and can be safely administered to patients in shock. In fact, a stabilising action of methoxyflurane on cardiorespiratory function has been reported (Virenque et al. 1975)

Penthrox®

Provides rapid pain relief

Average pain reduction from point of adminstration[1-2]



[1] COFFEY, Frank, et al., 2014. STOP!: A Randomised, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of Methoxyflurane For The Treatment Of Acute Pain; Emergecny Medicine Journal.
[2] BOLAND, Meredith, et al., 2007. A Randomized Controlled Trial Comparing Intranasal Fentanyl to Intravenous Morphine For Managing Acute Pain In Children In The Emergency Department; Emergency Medicine Journal.

Penthrox®

Can reduce patient waiting times to analgesia

Penthrox® assists by being:

- ✓ Self administered
- ✓ Easy to use
- ✓ Not a restricted drug (in Australia)
- ✓ Providing rapid non-opioid pain relief
- ✓ Able to drive home after treatment[1]
- ✓ Less observation time
- ✓ Earlier discharge



[1] NGUYEN, Nam, 2016. Psychomotor And Cognitive Effects Of 15-Minute Inhalation Of Methoxyflurane In Healthy Volunteers: Implication For Post-Colonoscopy Care; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110336/

[2] GROEGER, Lena, et al., 2017. ER Wait Watcher- State-by-state Waiting Times; ProPublica. https://projects.propublica.org/emergency/

Penthrox®

Can reduce resources used in pain management

Penthrox® provides rapid pain relief and is a cost effective option to increase patient flow & throughput

Pain is the most common presentation in the ED

Up to 78% of Emergency Department visits experience pain[1]

Penthrox® requires minimal supervision and is simple, portable, patient administered

Most common treatment for moderate to severe pain is IV opioids

The use of IV opioids is often the only reason an IV was administered

Inhalation of Penthrox® is non-invasive and does not require IV access or ongoing patient monitoring

Resources required for IV administration

- Bed/Room
- Equipment
- Nurses/Doctors
- Time
- 2 staff to access the opioids

Common use of IV opioids

30 year record in Australia of treating a wide range of painful conditions

Results of high resource use

Decreased patient flow
Cost to patient and hospital[2]
Takes staff away from other patients
IV resources required
Common use of IV opioids

[1]TODD, Knox, 2010. Chronic Or Recurrent Pain In The Emergency Department: National Telephone Survey Of Patient Experience; Western Journal of Emergency Medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3027428/
[2] PALMER, Pamela et al., 2016. Cost Of Delivering Intraveneous Opioid Analgesia In Emergency Departments In The United States; AcelRx

Penthrox®

Can reduce overcrowding in EDs



Overcrowding impact is recognized by the American College of Emergency Physicians (ACEP)

American College of Emergency Physicians (ACEP), 2016. Clinical & Practice Guidelines- Crowding; ACEP. https://www.acep.org/clinical---practice-management/crowding/

Penthrox®

Can reduce the cost of analgesia

Average costs of an IV Opioid treatment

Total Cost: $1,298



Average costs of a Penthrox® treatment*

Total Cost: $563*



Penthrox® could help to reduce the cost of analgesia by approximately $729 per patient, as it is non-invasive, requires less observation time and allows the patient to receive medical attention and be discharged earlier.

1 DIDONATO, K, et al, 2016. Intravenous Administration of Morphine In The Emergency Room Inflicts A Substantial Economic Burden In The EU5. Available from: http://www.acelrx.com/technology/publications/arx-04/Poster%20PSY45_06OCT2016.pdf
2 PALMER, Pamela et al., 2016. Cost Of Delivering Intraveneous Opioid Analgesia In Emergency Departments In The United States; AcelRx http://www.acelrx.com/technology/publications/arx-04/ISPOR%202016%20ER%20IV%20MS%20Poster%205%209%2016.pdf
3 FOLEY, Mathew, et al., 2008. Financial Impact of Emergency Department Crowding. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099606/
4 Cleveland Clinic, 2016. Patient Price Information List; http://my.clevelandclinic.org/ccf/media/files/Patients/cleveland-clinic-main-charges.pdf
5 Based on company estimates of 4-6 hours observation post IV administration compared with 2 hours of observation pre discharge when using Penthrox

*Based on company estimates

History of Penthrox

Clinical studies & publications to present

Pre-2005 Studies

- Obstetrics
- Obstetrics
- Dental
- Analgesia
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Post-Op
- Obstetrics
- Obstetrics
- Burns
- Burns
- Burns
- Burns
- Post-Op
- Obstetrics
- Obstetrics
- Obstetrics
- Obstetrics
- Dental
- Dental
- Burns
- Obstetrics
- Procedural
- Obstetrics
- Analgesia
- Prehospital
- ED
- Prehospital
- Analgesia



History of Penthrox

Clinical studies & publications to present

235,861 *patients have been studied in more than 75 clinical trials over 30 years*

Penthrox is used synominously with methoxyflurane

History of Penthrox

Clinical studies & publications to present

235,861 patients



Penthrox is used synominously with methoxyflurane

Future of Penthrox

Value Proposition

Non-narcotic trauma relief, non-addictive, safe.[1]

Not a restricted medicine

Penthrox can materially improve the throughput of patients[7,8] in the ER. It enables better time to analgesia and less medical care and observation compared with opioids.

In 2008 the average cost for an ER bed for a category 4 trauma in the USA was USD$1298[4] (without medical care or medication costs). Penthrox could materially reduce the cost of treatment.

Penthrox improves time to nalgesia.[5,6]

The average time spent in the ER if you have a narcotic is approximately 6 hours. Penthrox could reduce that by more than 50%.[3]



You can drive home and go back to work after Penthrox.[2]

1. Penthrox Summary of Product Characteristics (SPC), 2015
2. Nguyen et al., Journal of Gastroenterology and Hepatology, 30 (Suppl. 3): 55, 2015
3. Company estimate
4. US Agency for Healthcare Research and Quality. Emergency Room Services-Mean and Median Expenses per Person With Expense and Distribution of Expenses by Source of Payment: 2008. Medical Expenditure Panel Survey Household Component Data.
5. Sokoloff et al. BMJ Open 2014; 4e004288. doi:10.1136/bmjopen-2013-004288
6. Ng et al. Clinical Evaluation of Penthrox® (Methoxyflurane) and Tramadol for the Singapore Emergency Ambulance Service. SEMS. 27 Feb 2016.
7. Spruyt et al., BMJ Supportive & Palliative Care, 4(4):342-8. 2014
8. Nguyen et al. Endosc Int Open. 3(5): E487-93. 2015.

Future of Penthrox

Potential global sales for Acute Trauma pain $2 billion+



*Bases on company estimates including assumptions around market penetration and reimbursement levels

Future of Penthrox

Potential global sales for Breakthrough pain $6 billion+

Peak sales in USA could be $2 billion per annum*

Peak sales in Europe could be $2 billion per annum*



Peak sales in Asia could be $1.5 billion per annum*

Peak sales in Latin America could be $500 million per annum*

Peak sales in MENA could be $300 million per annum*

*Bases on company estimates including assumptions around pricing, market penetration and reimbursement levels

Future of Penthrox

Potential global sales for Minor Surgical Procedures $2.3 billion+



*Based on company estimates including assumptions around pricing, market penetration and reimbursement levels

Future of Penthrox

Potential global sales for Home Use $3 billion+

Peak sales in USA could be $900 million per annum*

Peak sales in Europe could be $1 billion per annum*



Peak sales in Asia could be $620 million per annum*

Peak sales in Latin America estimated to be $230 million per annum*

Peak sales in MENA could be $140 million per annum*

*Bases on company estimates including assumptions around pricing, market penetration and reimbursement levels

Future of Penthrox

USA

MVP submitted a detailed regulatory package to the FDA in January 2016. We received a written response from the FDA detailing it's opinion on the strengths of our regulatory package and by inference the work required to get Penthrox approved for sale in the United States of America.

Amongst those requirements is the need to perform a Pivotal Phase III Clinical Trial (in addition to the STOP study and Bone Marrow Biopsy Phase III studies which MVP has successfully completed).

MVP has commenced the clinical work required and estimate it will take 2+ years and circa $15 million to complete.

MVP has a track record of successfully completing clinical programs, including Phase III studies on time and budget.

Future Of Penthrox®

Penthrox® clinical program for USA



Future of Penthrox

Clinical development program

Additional clinical trials and studies are planned for FY17 (and beyond) which will broaden the indications for use of Penthrox® including:

We are developing a program of work to support additional indications for Penthrox worldwide. Our longer term ambition is to extend the use of Penthrox into:

- Acute Pain / Minor Surgical Procedures;
- Breakthrough Pain / Repeat Use; and ultimately; and
- Home Use.

Acute Pain & Minor Surgical Procedures

Penthrox is already approved for use in Minor Surgical Procedures in Australia and elsewhere.

MVP is working with its partners to develop a clinical program to extend the indication of use in markets around the world. We hope to achieve this extension in Europe within the next 2+ years.

We estimate the market for Minor Surgical Procedures globally could be $3 billion.

Future of Penthrox

Clinical development program

Breakthrough Pain / Repeat Use

MVP has begun the clinical program to get Penthrox approved for sale in the USA. As part of that program, several pre-clinical trials will be concluded. These trials will also be used towards the work program required to have the indication for Penthrox extended to Repeat Use and Breakthrough Pain where Penthrox could be the ideal alternative to high potency and dangerous opioids currently used in the vast majority of cases.

We estimate the market for Breakthrough Pain could be $6 billion.

Home Use

Ultimately, we hope the clinical programs we undertake will allow Penthrox to be approved for home use via prescription.

Our vision is that households all over the world will have a Penthrox device for use during those rare occasions when trauma grade, non-opioid analgesia is required.

Penthrox

Intellectual Property

MDI is protecting its future by generating intellectual property from its manufacturing technology and delivery devices.

MDI has filed and is managing the following patents and trademarks:

- 6 Penthrox Inhaler patents;
- 1 manufacturing patent; and
- Numerous trademark filings to mirror global growth.

MDI is also generating significant “Data Exclusivity” rights from its successful regulatory approvals around the world.

Note: “Data Exclusivity” works like a patent and protects the product in market from competition but usually for a shorter period of time.

Penthrox

Manufacturing

MDI has invested millions of dollars developing new manufacturing technology, techniques and methods.

MDI has:

1. Intellectual property.
2. Global production capacity.
3. Lowest cost to manufacture.
4. Significant competitive advantage.

Penthrox
Outlook

MVP's ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months we expect to:

1. Obtain approval to sell Penthrox in more than 20 countries throughout Europe and in a number of courtiers outside the EU;
2. Conclude additional distribution partnership for new countries;
3. Commence and progress work on gathering the clinical data needed to submit a "New Drug Application" to the Food & Drug Administration in the USA, and extend the 'indications for use' for Penthrox;
4. Commence work to develop new manufacturing process for Analgesic and Anaesthetic products and create significant the intellectual property; and
5. Complete our manufacturing facility which will have special purpose Research and Development laboratories dedicated to improving the way we manufacture Penthrox.

Introducing Respiratory Devices

MDI Medical

Respiratory division

MDI has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication.

In 2011 MDI launched a new range of products using MDI's Cross Valve Technology™, a patented system of drug delivery which ensures very low resistance during inhalation and exhalation, while maximising the dose of medication available.

In 2015 MDI invested in developing its own particle size distribution testing and design laboratory.

2016 MDI received FDA approval to sell its range of Anti Static Space Chamber devices in the USA and elsewhere.

MDI Medical

Respiratory division

MDI offers a range of devices that can be used to help patients manage and take control of their asthma and COPD.

- Space Chamber Plus™ anti-static range
- Space Chamber Plus™ aerosol spacer
- Space Chamber™ re-usable
- Compact Spacer Chamber Plus™
- Breath-A-Tech™ spacer range
- Breath-Alert® peak flow meter
- EZ-fit face masks
- KDK oxygen regulators

Respiratory Devices

Existing distribution network



Respiratory Division

Future

MDI respiratory products:

- now sell in 20 countries
- are ranged in 1600 pharmacies across the USA
- have achieved full reimbursement in the USA
- are Australia's leading brand
- are delivering strong growth around the world

Respiratory Division

Future

MDI is investing heavily in developing new and innovative products

- Anti static spacers
- Anti static mask – (1st of its kind)
- Collapsible spacer
- Economical spacer
- Additional patentable devices and technology

Two new products are expected to be launched during 2017.

Respiratory Devices

Intellectual Property

MDI is protecting its future by generating intellectual property from its new range of respiratory devices.

MDI has filed a number of global patents.

MDI has filed international Trade Marks and Registered Designs in more than 20 countries.

Respiratory Devices

Outlook

MVP's ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 18 countries.

Over the next 12 months we expect to:

1. Obtain additional partnership deals in the USA and deliver sales growth;
2. Obtain additional partnership deals in other countries around the world;
3. Consolidate our position as the largest supplier of Respiratory Devices in Australia;
4. Introduce new products; and
5. Continue to drive down costs and increase the range and quality of our products.

Introducing MVP Corporate

Financial Summary of H1FY17

34% REVENUE



42% RECEIPTS FROM CUSTOMERS



24% GROSS MARGIN



142% RESPIRATORY SALES



14% PENTHROX SALES



Financial Summary of H1FY17

- ☑ 34% growth in revenue to a record $8.05m
- ☑ 74% growth in Net Profit after Tax to $410,000
- ☑ 24% growth in Gross Margin
- ☑ 51% growth in EBITDA
- ☑ 82% growth in Profit before Tax
- ☑ 14% growth in Penthrox® revenue
- ☑ 108% growth in International Penthrox® revenue

Financial Summary of H1FY17

- 142% growth in Global Respiratory Device sales
- 192% growth in Australian Respiratory Device sales
- 159% growth in European Respiratory Device sales
- 148% growth in USA Respiratory Device sales
- 42% increase in Cash Receipts from customers

Financial Summary

MDI has been profitable every year since listing on the ASX in 2003 and used those profits for registration and additional clinical studies and:

- has generated a positive cash flow every year;
- pays tax and has paid fully franked dividends;
- has received almost $18.5 million in upfronts and milestones in the last 15 months; and
- expects a further $7 million in milestone payments to be received over the next 18 months.

MDI Investor Dashboard (ASX: MVP)

Historical Stock Chart (3yr)



Current Stock Price

5.00 ▲ 0.280 (5.93%)

2 Mar, 12:00pm

Day High	5.080
Day Low	4.810
Open	4.810
Prev. Close	4.720
Avg. Volume	63,642
52 Wk. High	6.850 (3 May 2016)
52 Wk. Low	4.120 (6 Dec 2016)
Mkt. Cap	294.34 (Mil)

MDI Corporate Overview

David Williams

Non-Executive Chairman

The Managing Director of Kidder Williams Ltd, with 32 years experience in investment banking.

Dr Harry Oxer

Non-Executive Director

A Medical Consultant to MVP and St John Ambulance in Western Australia.

Leon Hoare

Non-Executive Director

Recent Managing Director of Smith & Nephew in Australia and New Zealand.

Max Johnston

Non-Executive Director

Recent MD of J&J Asia Pacific. A Non-Executive Director of Enero Group Ltd, Polynovo Limited and Chairman of Probiotec Limited.

Allan McCallum

Non-Executive Director

Over 15 years public companies experience including an ASX 50 company.

Phillip Powell

Non-Executive Director

A Chartered Accountant and has an extensive finance background.

John Sharman

Chief Executive Officer

Mark Edwards

Group Financial Controller & Company Secretary

Glenn Gilbert

Associate Director, Commercial

Scott Courtney

Director of Operations & Research

Maggie Oh

Director of Scientific Affairs

Keith Jeffs

General Manager, Sales & Marketing

Jake Golding

Quality Assurance & Validation Manager

MDI Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)

New Business Partners

Product innovation
(worlds best manufacturing processes and delivery devices resulting in significant IP)

Clinical trials
(Commercial clinical studies to support marketing and product development)

Regulatory Approval and new markets

Contact Details

HEAD OFFICE

4 Caribbean Drive

Scoresby, Victoria, Australia, 3179

Tel: +61 3 9547 1888

Fax: +61 3 9547 0262

Web: www.medicaldev.com

Medical Developments International